Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2023 08:30 ET | Source: Apollomics Inc.

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

FOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address...
October 26, 2023 08:50 ET | Source: Apollomics Inc.

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a...
October 23, 2023 08:30 ET | Source: Apollomics Inc.

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

FOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG...
October 16, 2023 18:55 ET | Source: Apollomics Inc.

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to...
September 28, 2023 16:17 ET | Source: Apollomics Inc.

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash,...
September 06, 2023 07:00 ET | Source: Apollomics Inc.

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to...
April 11, 2023 08:30 ET | Source: Apollomics, Inc.

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium

FOSTER CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address...
March 30, 2023 08:00 ET | Source: Apollomics, Inc.

Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq

FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to...
November 15, 2022 08:00 ET | Source: Apollomics, Inc.

Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations

FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and...
September 14, 2022 08:30 ET | Source: Apollomics, Inc.

Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.

– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet...